Back to today’s briefing

Story perspectives

AbbVie Beats Earnings but Stock Dips Amid Humira Decline

2/5/2026

50 8 Full Breakdown

Summary

Story summary

AbbVie reported fourth-quarter 2025 sales of $16.62 billion, topping expectations as Skyrizi and Rinvoq lifted results.
Skyrizi sales rose 32.5% to $5.01 billion.
Rinvoq sales rose 29.5% to $2.37 billion.
Humira sales declined 25.9% to $1.25 billion amid biosimilar competition.
AbbVie stock fell nearly 6% after the earnings release.

History

Historical Context

Humira, approved in 2002, dominated the pharmaceutical market until its patent expired in 2016, allowing biosimilars to enter. This shift resulted in a 25.9% decline in Humira sales, totaling $1.25 billion. As AbbVie adapts, sales of its newer drugs, Skyrizi and Rinvoq, surged, highlighting the ongoing competition reshaping the pharmaceutical landscape and challenging established products.

1 of 2

Story summary

AbbVie reported fourth-quarter 2025 sales of $16.62 billion, topping expectations as Skyrizi and Rinvoq lifted results.
Skyrizi sales rose 32.5% to $5.01 billion.
Rinvoq sales rose 29.5% to $2.37 billion.
Humira sales declined 25.9% to $1.25 billion amid biosimilar competition.
AbbVie stock fell nearly 6% after the earnings release.

1 / 2